Fresenius SE & Co. KGaA Inh.-Akt.(Spons.ADRs) 1/4/o.N. Aktie

Fresenius SE & Co. KGaA operates as a global healthcare provider, delivering a comprehensive suite of products and services across dialysis, hospital management, and outpatient medical care. Its operations are structured across four principal divisions. Fresenius Medical Care is dedicated to patients suffering from chronic kidney failure, providing essential dialysis products such as dialyzers, hemodialysis machines, and associated disposables, alongside comprehensive dialysis services. Fresenius Kabi concentrates on the treatment and care of acutely and chronically ill individuals. Its extensive portfolio encompasses intravenous (IV) drugs – including generics for oncology, pain management, anesthesia, and critical care – as well as parenteral and enteral nutrition solutions, infusion therapies, blood volume expanders, and biosimilar drugs targeting autoimmune and oncological conditions. Kabi also supplies the necessary medical devices for administering these therapies and transfusion products for blood component collection. Fresenius Helios manages a vast network of medical facilities. In Germany, it oversees 90 hospitals, approximately 130 outpatient clinics, and six prevention centers. Its Spanish footprint includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. Furthermore, Helios extends its reach into fertility treatments, operating 33 clinics and an additional 39 sites spanning 10 countries across three continents. Fresenius Vamed specializes in the development, planning, and operational management of hospitals and other healthcare infrastructure. Its services range from project development and turnkey construction to ongoing maintenance, technical oversight, and full operational management. Established in 1912 and headquartered in Bad Homburg vor der Höhe, Germany, the company adopted its current name, Fresenius SE & Co. KGaA, in January 2011, having previously been known as Fresenius SE.